Astec LifeSciences LimitedQ1 FY27 Results & Financial Update
Astec LifeSciences Limited: Q1 FY27 consolidated results and company financials – revenue ₹83.56 Cr, PAT ₹-18.71 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Astec LifeSciences price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Astec LifeSciences Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Despite the lower revenue base, the company successfully achieved an EBITDA breakeven of ₹0.1 crore in Q1 FY27, recovering from an EBITDA loss of ₹10.5 crore in Q1 FY26, aided by a favourable product mix and enhanced manufacturing capacity utilisation.
Management noted that the broader agrochemical sector continues to contend with a persistent demand-supply imbalance originating in 2023, though market conditions are anticipated to equilibrate over the medium term.
Operating performance during the quarter benefited from improved margins across both the Enterprise and Contract Manufacturing segments, alongside higher operational efficiencies at plant facilities.
The enterprise products segment demonstrated strong volume-led growth, while contract manufacturing revenues experienced a contraction due to a demanding base period in the prior year.
Profit after tax was ₹-18.71 Cr for the reported quarter. EPS was ₹-8.40 for the reported quarter.
01 · Business model
What does Astec LifeSciences do?
Astec LifeSciences Limited, incorporated in 1994, is engaged in the manufacturing of agrochemical active ingredients (technical), bulk agrochemicals, formulations, and intermediate products.
The company maintains a balanced sales mix across domestic markets and over 18 international destinations, including the United States, Europe, West Asia, South-East Asia, Latin America, and Africa.
Operating through both enterprise product lines and contract manufacturing and new product development (CDMO) verticals, Astec serves global agrochemical brand owners and agricultural input markets.
02 · Historical context
What shaped the business before this quarter
Management noted that the agrochemical sector has been dealing with an ongoing demand-supply imbalance since 2023, influencing operational conditions across the industry.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹83.56 Cr |
| Total income | ₹84.29 Cr |
| Profit before tax | ₹-18.74 Cr |
| Profit after tax | ₹-18.71 Cr |
| EPS | ₹-8.40 |
Financial interpretation
What the reported numbers mean
Profit after tax represented -22.4% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to -22.4% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹0.73 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from Enterprise Products expanded by 42% year-on-year to ₹51.8 crore in Q1 FY27, up from ₹36.5 crore in Q1 FY26, driven primarily by higher volumes and supported by improved realisations.
Revenue from Contract Manufacturing & New Products (CDMO) stood at ₹31.8 crore in Q1 FY27 compared to ₹54.6 crore in Q1 FY26, with the year-on-year decline attributed largely to a high base in the corresponding quarter of the previous year.
What drove margins
EBITDA reached breakeven at ₹0.1 crore compared to an EBITDA loss of ₹10.5 crore in Q1 FY26, driven by a favourable product mix, improved margins in both Enterprise and CDMO segments, and enhanced capacity utilisation across manufacturing plants.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Enterprise segment revenues recorded ₹51.8 crore in Q1 FY27, reflecting a 41.6% increase over ₹36.5 crore in Q1 FY26.
Contract Manufacturing & New Products segment recorded revenues of ₹31.8 crore in Q1 FY27, representing a 41.8% decline compared to ₹54.6 crore in Q1 FY26.
Geography and market mix
Domestic revenues increased by 11.3% to ₹50.3 crore in Q1 FY27 from ₹45.2 crore in Q1 FY26.
Export revenues declined by 27.5% to ₹33.3 crore in Q1 FY27 compared to ₹45.9 crore in Q1 FY26.
06 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company reported enhanced capacity utilisation across its manufacturing plants, which supported operating margin improvements during the quarter.
07 · Strategy & new businesses
How the company is trying to change its growth mix
The company is taking active steps to build its business development and growth capabilities alongside new product introductions, while exploring operational efficiencies across its facilities.
08 · Reported developments
What changed operationally
Enterprise products revenue grew 42% year-on-year to ₹51.8 crore, supported by higher volumes and improved realisations.
09 · Pressure points & risks
What is not going smoothly
CDMO product revenue declined 41.8% year-on-year to ₹31.8 crore due to a high comparative base in Q1 FY26.
Export revenues contracted by 27.5% year-on-year to ₹33.3 crore.
The company reported a net loss after tax of ₹18.7 crore for the quarter, albeit lower than the loss of ₹33.0 crore in Q1 FY26.
10 · Beyond the numbers
What changed beyond the numbers
Reported update
Sector Outlook Commentary
Management noted expectations that the agrochemical sector demand-supply imbalance since 2023 will even out over the medium term, structurally supporting the industry.
11 · Key Q&A
The quarter, answered directly
What does Astec LifeSciences do?
Astec LifeSciences Limited, incorporated in 1994, is engaged in the manufacturing of agrochemical active ingredients (technical), bulk agrochemicals, formulations, and intermediate products.
What is the clearest takeaway from Q1 FY27?
Despite the lower revenue base, the company successfully achieved an EBITDA breakeven of ₹0.1 crore in Q1 FY27, recovering from an EBITDA loss of ₹10.5 crore in Q1 FY26, aided by a favourable product mix and enhanced manufacturing capacity utilisation.
What drove revenue or demand?
Revenue from Enterprise Products expanded by 42% year-on-year to ₹51.8 crore in Q1 FY27, up from ₹36.5 crore in Q1 FY26, driven primarily by higher volumes and supported by improved realisations.
What mattered most for margins or profitability?
EBITDA reached breakeven at ₹0.1 crore compared to an EBITDA loss of ₹10.5 crore in Q1 FY26, driven by a favourable product mix, improved margins in both Enterprise and CDMO segments, and enhanced capacity utilisation across manufacturing plants.
What changed operationally beyond the headline numbers?
The company reported enhanced capacity utilisation across its manufacturing plants, which supported operating margin improvements during the quarter.
What are the main pressure points disclosed for the quarter?
CDMO product revenue declined 41.8% year-on-year to ₹31.8 crore due to a high comparative base in Q1 FY26.
12 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
13 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Medium-Term Demand Rebalancing: Monitor industry-wide demand-supply equalisation in the agrochemical sector and its impact on export volumes and CDMO segment order inflows.
- 02
Plant Efficiency and Margin Trajectory: Track the progression of capacity utilisation rates and profitability across both Enterprise and Contract Manufacturing segments in subsequent quarters.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.